Syndax Pharmaceuticals (SNDX) Stock Price, Quote, News & History

Comments

Syndax Pharmaceuticals Inc (SNDX) Stock Price, Quote, News & History

SNDXNASDAQ

Trade with Public

$24.65

0.401.65%

Last update: Apr 14, 10:53 AM

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$24.27

Close

-

Volume / Avg.

92.57K / 1.37M

Day Range

$24.18 - $24.80

52 Wk Range

8.58 - 25.59

Market Cap

$2.14B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

26.86%

Days to Cover

13.63

Recent Syndax Pharmaceuticals Inc News

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

Avi Kapoor

This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious post-transplant condition.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-322.98M

Investing Cash Flow (TTM)

290.04M

Financing Cash Flow (TTM)

13.68M

Free Cash Flow (TTM)

-323.17M

Capital Expenditure (TTM)

-187.00K

Net Change in Cash (TTM)

-19.27M

Analyst Trends and Forecast

3

Oct 25

4

Nov 25

1

Dec 25

4

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.07B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

12.19

PB Ratio (TTM)

33.09

Earnings Yield % (TTM)

-13.57%

Earnings Yield % (FWD)

-6.85%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.73

Company Debt

Total Debt

$343.91M

LT Debt

$343.91M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$134.93M

Debt to Equity

5.34

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$24.27

Close

-

Volume / Avg.

92.57K / 1.37M

Day Range

$24.18 - $24.80

52 Wk Range

8.58 - 25.59

Market Cap

$2.14B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

26.86%

Days to Cover

13.63

About

Sector

Health Care

Industry

Biotechnology

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Syndax Pharmaceuticals (SNDX) stock?

A

You can purchase shares of Syndax Pharmaceuticals (NASDAQ:SNDX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Syndax Pharmaceuticals (SNDX) competitors?

A

Other companies in Syndax Pharmaceuticals’s space includes: Immunome Inc (NASDAQ:IMNM), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Sarepta Therapeutics Inc (NASDAQ:SRPT), Ascentage Pharma Group International (NASDAQ:AAPG) and Day One Biopharmaceuticals Inc (NASDAQ:DAWN).

Q

What is the forecast, or price target, for Syndax Pharmaceuticals (SNDX) stock?

A

Syndax Pharmaceuticals has a consensus price target of $38.00.

Q

What is the current price for Syndax Pharmaceuticals (SNDX)?

A

The stock price for Syndax Pharmaceuticals (NASDAQ: SNDX) is $24.65 last updated April 14, 2026 at 10:53 AM EDT.

Q

Does Syndax Pharmaceuticals (SNDX) pay a dividend?

A

There are no upcoming dividends for Syndax Pharmaceuticals.

Q

When is Syndax Pharmaceuticals (NASDAQ:SNDX) reporting earnings?

A

Syndax Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Syndax Pharmaceuticals (SNDX) going to split?

A

There is no upcoming split for Syndax Pharmaceuticals.

Q

What sector and industry does Syndax Pharmaceuticals (SNDX) operate in?

A

Syndax Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Ultragenyx Pharmaceutical Inc

NASDAQ:RARE

$24.31

2.88%

Sarepta Therapeutics Inc

NASDAQ:SRPT

$22.04

1.16%

Ascentage Pharma Group International

Day One Biopharmaceuticals Inc

Agios Pharmaceuticals Inc

NASDAQ:AGIO

$33.56

1.24%

Key Statistics

Open

$24.27

Close

-

Volume / Avg.

92.57K / 1.37M

Day Range

$24.18 - $24.80

52 Wk Range

8.58 - 25.59

Market Cap

$2.14B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

26.86%

Days to Cover

13.63

Recent Syndax Pharmaceuticals Inc News

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

Avi Kapoor

This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious post-transplant condition.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-322.98M

Investing Cash Flow (TTM)

290.04M

Financing Cash Flow (TTM)

13.68M

Free Cash Flow (TTM)

-323.17M

Capital Expenditure (TTM)

-187.00K

Net Change in Cash (TTM)

-19.27M

Analyst Trends and Forecast

3

Oct 25

4

Nov 25

1

Dec 25

4

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.07B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

12.19

PB Ratio (TTM)

33.09

Earnings Yield % (TTM)

-13.57%

Earnings Yield % (FWD)

-6.85%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.73

Company Debt

Total Debt

$343.91M

LT Debt

$343.91M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$134.93M

Debt to Equity

5.34

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$24.27

Close

-

Volume / Avg.

92.57K / 1.37M

Day Range

$24.18 - $24.80

52 Wk Range

8.58 - 25.59

Market Cap

$2.14B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

26.86%

Days to Cover

13.63

About

Sector

Health Care

Industry

Biotechnology

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry